Danaher Corporation (DHR)
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors
Danaher (DHR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DHR crossed above the 20-day moving average, suggesting a short-term bullish trend.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core revenue gains expected in 2026.
Why Is Danaher (DHR) Down 7% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Danaher Q1 2026 Earnings Update
Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q'26. Life Sciences segment's core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q'25.
Danaher Q1 Earnings Call Highlights
Danaher (NYSE: DHR) reported first-quarter 2026 sales of $6.0 billion, with core revenue up 0.5% year over year as strength in bioprocessing and better-than-expected life sciences performance largely offset a lighter-than-normal respiratory season at Cepheid. President and CEO Rainer Blair said the company delivered "better than expected adjusted EPS growth" by "leveraging the Danaher Business System
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR beats Q1 EPS estimates and lifts 2026 outlook, but revenues miss as Diagnostics lags while bioprocessing strength and Masimo deal shape growth plans.
